CDSCO Replaces Approval Gate with Digital Intimation for Early Drug Testing

CDSCO has restructured the entry point for early-stage drug testing and research and development activity in India, shifting from a formal approval requirement to a prior intimation mechanism delivered through the National Single Window System portal. For plant heads and regulatory affairs leads at multinational pharma companies and CDMOs with India-facing development pipelines, the change resets the administrative clock on preclinical and early clinical work, compressing a stage of the regulatory pathway that has historically added weeks to project timelines.

The prior intimation system replaces the need to obtain explicit regulatory clearance before initiating certain drug testing and R&D activities. Under the revised framework, sponsors and manufacturers submit notification through the NSWS portal rather than waiting for a formal approval decision from CDSCO. The move is designed to reduce administrative lag at the earliest stages of drug development, where timeline compression has the most pronounced effect on overall programme velocity. For CDMOs managing multiple early-stage programmes simultaneously, the cumulative reduction in queue time across a portfolio could be operationally significant.

The NSWS portal serves as India's centralised digital interface for regulatory and government submissions, and CDSCO's integration of the prior intimation workflow into that infrastructure signals a broader directional shift toward digitised, process-driven oversight rather than transactional approval cycles. QA directors and regulatory affairs leads should note that intimation-based systems place greater internal compliance burden on the submitting organisation: the onus of ensuring that activities fall within the permitted scope of the intimation rests with the sponsor, not the regulator. Documentation discipline, internal SOPs governing what triggers an intimation versus a full application, and audit-readiness for CDSCO inspections will require review in light of the new pathway.

For multinational companies navigating Indian regulatory submissions alongside ICH Q10-aligned quality systems, the practical question is how the intimation framework maps onto existing stage-gate processes. Where a formal CDSCO approval previously served as a documented hold point in development workflows, the intimation model requires organisations to establish equivalent internal controls that satisfy both their own quality management systems and any GMP expectations that apply to the facilities conducting the work. Regulatory affairs teams should engage with local counsel and regulatory consultants to define the precise scope of activities covered under the new system before updating submission strategies.

CDSCO announced the prior intimation system via the NSWS portal as part of an effort to fast-track drug testing and R&D timelines and boost innovation in early-stage drug development. The measure was reported by Media4Growth and Indian Pharma Post on 20 April 2026. Pharma Now will continue to track implementation guidance and any subsequent CDSCO circulars that define the operational boundaries of the intimation pathway.